Recombinant human Insulin-like Growth Factor (IGF-II) protein (GF-060)

$300.00


Human IGF-II is a potent mitogen for cells of mesodermal origin. It is composed of 67 amino acid residues, and is 62% homologous with human IGF-I. Human IGF-II is produced by genetically engineered yeast, and purified by sequential chromatography. This recombinant protein has a size of 7.5 kDa.
Alternative names C11orf43, IGF 2, IGF II, IGF-II, IGF2, IGF2_HUMAN, IGFII, INSIGF, Insulin like Growth Factor 2, insulin like growth factor 2 (somatomedin A), Insulin like growth factor II, Insulin like growth factor II precursor, Insulin like growth factor type 2, pp9974, Preptin, putative insulin like growth factor II associated protein, Somatomedin A, Somatomedin-A
Type Recombinant.
Source Yeast


Description

Product name Recombinant human Insulin-like Growth Factor (IGF-II) protein (GF-060)
Catalog number GF-060-5
Brand family Austral Biologicals
Product type Proteins and Peptides


Biological Information

Purity Over 95% (N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis)
Purification method Purified by sequential chromatography


Target

SwissProt ID Link P01344
Gene Aliases IGF2, PP1446 (ORF)
Function The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development.
Preptin undergoes glucose-mediated co-secretion with insulin, and acts as physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3
Subcellular Location Secreted
Involvement in Disease The gene represented in this entry is involved in disease pathogenesis. Most of the cases of Silver-Russell syndrome are caused by the epigenetic changes of DNA hypomethylation at the telomeric imprinting control region (ICR1) on chromosome 11p15, involving the H19 and IGF2 genes.

Disease description: A clinically heterogeneous condition characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations. The phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age.
Post-Translational Modification O-glycosylated with core 1 or possibly core 8 glycans. Thr-96 is a minor glycosylation site compared to Thr-99
Sequence Similarities Belongs to the insulin family


Poduct Presentation

Form Lyophilized powder


Storage and Shipping Information

Storage Store at +4 ºC. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80 ºC is recommended


References and Citations

Citations 1. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ. (New York).
2. Nissley, S.P. and Rechler, M.M. (1884) in Hormonal Proteins and Peptides. Ed. Li., C.H., pages 127-203. Academic Press (New York)